Background The clinical benefit of inhaled antibiotics in non-cystic fibrosis bronchiectasis
has not been established in randomised controlled trials. We aimed to assess safety and …

Background Although use of inhaled antibiotics is the standard of care in cystic fibrosis,
there is insufficient evidence to support use of inhaled antibiotics in patients with …

We conducted a meta-analysis of randomised trials to evaluate the efficacy and safety of
inhaled antibiotics in patients with stable non-cystic fibrosis (CF) bronchiectasis. We …

Background Azithromycin is a macrolide antibiotic with anti-inflammatory and
immunomodulatory properties. We tested the hypothesis that azithromycin would decrease …

Abstract Background and Aims The evidence supported the use of nebulized antibiotics in
non‐cystic fibrosis (non‐CF) bronchiectasis is indefinite. A meta‐analysis was performed to …

BACKGROUND: Previous aztreonam for inhalation solution (AZLI) studies included patients
with cystic fibrosis, Pseudomonas aeruginosa (PA) airway infection, and forced expiratory …

We describe our institutional efficacy experience of azithromycin 250mg thrice weekly in
adult non-cystic fibrosis bronchiectasis. METHODS: Eligibility criteria for prophylactic …

Background Bronchiectasis guidelines recommend antibiotics for the treatment of acute
respiratory exacerbations, but randomised placebo-controlled trials in children are lacking …

There are strong data supporting using the use of aerosolized antibiotics for the treatment of
Gram-negative infections in patients with cystic fibrosis (CF). The regular use of aerosol …

Background The delivery of antipseudomonal antibiotics by inhalation to Pseudomonas
aeruginosa-infected subjects with non-cystic fibrosis (CF) bronchiectasis is a logical …